Nantahala Capital Management portfolio
Type not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · amendment (replaces the original: filed as “new holdings”, but it restates the full portfolio) of Aug 19, 2026 ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Nantahala Capital Management reported a $1.7 bn portfolio of 131 positions to the SEC as of the end of Q2 2026. Its largest positions are TBBK, BVS, HGV. During the quarter it opened Adma Biologics and Vor Biopharma.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Nantahala Capital Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Sep 30, 2026 · filed Oct 7, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Plus 10 more, in its EDGAR filings.
What changed this quarter
92 positions with a change (14 new, 24 added to, 40 trimmed, 14 sold); also, 5 entered through an IPO, 5 exited through an acquisition or merger, 2 entered through a spin-off. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Establishment Labs Holdings−60%fewer sharesReduced3.0% → 1.7%
- Peloton Interactive−57%fewer sharesReduced3.2% → 1.8%
- Hilton Grand Vacations−32%fewer sharesReduced3.7% → 3.3%
- Tango Therapeutics−60%fewer sharesReduced1.6% → 0.9%
- Anteris Technologies Global−39%fewer sharesReduced1.9% → 2.0%
- Adma Biologics+1.2 ppof portfolioNew— → 1.2%
- Vor Biopharma+0.9 ppof portfolioNew— → 0.9%
- Planet Fitness+0.9 ppof portfolioNew— → 0.9%
- Inspire Medical Systems+0.7 ppof portfolioNew— → 0.7%
- Avalo Therapeutics+51%more sharesIncreased1.2% → 2.1%
- Zevra Therapeutics−29%fewer sharesReduced1.5% → 1.6%
- Inventiva+0.6 ppof portfolioNew— → 0.6%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- BancorpTBBK4.7%
- BioventusBVS3.4%
- Hilton Grand VacationsHGV3.3%
- SavaraSVRA2.6%
- Eton PharmaceuticalsETON2.6%
- Amneal PharmaceuticalsAMRX2.4%
- EvolusEOLS2.4%
- Avalo TherapeuticsAVTX2.1%
- LB PharmaceuticalsLBRX2.1%
- Anteris Technologies GlobalAVR2.0%
- Abeona TherapeuticsABEO1.9%
- Peloton InteractivePTON1.8%
- Establishment Labs HoldingsESTA1.7%
- Xtant Medical HoldingsXTNT1.7%
- JACK In the BoxJACK1.7%
Portfolio by sector
- ● Health Care 62%
- ● Consumer Discretionary 15%
- ● Financials 6%
- ● Information Technology 5%
- ● Industrials 4%
- ● SPAC / vehículos 2%
- ● Communication Services 2%
- ● Materials 1%
- ● Consumer Staples 1%
- ● Real Estate 1%
13F filings with amendments or confidential positions
Declared options (23)
Besides stocks, Nantahala Capital Management declared 7 puts (they gain if the stock falls) and 16 calls (they gain if it rises) with a notional of $1.4 bn. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTiShares Russell 2000 ETFIWM$601M
- CALLPeloton InteractivePTON$97.2M
- CALLHerbalifeHLF$86.8M
- CALLViatrisVTRS$79.4M
- PUTEdwards LifesciencesEW$72.4M
- PUTState Street SPDR S&P Biotech ETFXBI$63.3M
- CALLHilton Grand VacationsHGV$56.3M
- PUTETF SER SolutionsQTUMnew this quarter$36.9M
- CALLuniQureQURE$36.8M
- CALLNeurocrine BiosciencesNBIXnew this quarter$33.7M
- PUTPraxis Precision MedicinesPRAXnew this quarter$33.5M
- PUTKrystal BiotechKRYSnew this quarter$31.6M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified: we have not assigned a type because we found no document that is enough to tell. Most 13F filers are in this situation: we only review in depth those that meet the portfolio criteria.
Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions; its top 10 positions are under 45%; more than 20% is options. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- First Light Asset ManagementInvestment firm · $1.6 bn
- Vantage Investment Partners$1.7 bn
- Triodos Investment Management BVInvestment firm · $1.6 bn
- MPM BioimpactInvestment firm · $1.6 bn
- No Street GPInvestment firm · $1.7 bn
- Kopernik Global InvestorsInvestment firm · $1.6 bn